DSIP
ProtocolScheduling DSIP alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.
Key Takeaways
Scheduling lens: DSIP's ~7 min plasma; CNS effects longer half-life via subq/intranasal places it in the multi-daily-dosing bucket. Mechanism: Mechanism remains incompletely characterised. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Protocol calendar planning for DSIP is shaped by mechanism, pharmacokinetics, and operational reality. Mechanism remains incompletely characterised. Effects observed on delta-wave (slow-wave) sleep promotion, opioid receptor modulation indirectly via μ-receptor systems, and HPA axis dampening. Crosses the blood-brain barrier. The subsections below work through the daily timing patterns, the 8-12 week cycle structure with calibrated off-period, the stack scheduling principles, and the travel-and-disruption playbook.
Cycle length and off-cycle planning
Standard DSIP cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any DSIP protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most DSIP schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Daily and weekly timing
DSIP with a ~7 min plasma; CNS effects longer half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either 1x daily before sleep, with consistency mattering more than the absolute clock time of any single dose.
The most-asked scheduling question for DSIP in stack scheduling is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
Schedule design for DSIP in weekly timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
For travel considerations scheduling, DSIP is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
The most-asked scheduling question for DSIP in wash-out is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 100-500 mcg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 60-500 mcg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 100-500 mcg | 1x daily before sleep |
| Maintenance phase | SubQ | 70-500 mcg | Ongoing with periodic pauses |
Dose timing for DSIP is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
DSIP stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- DSIP + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with DSIP's mechanism in protocol / scheduling / cycling protocols.
- DSIP + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with DSIP's mechanism in protocol / scheduling / cycling protocols.
- DSIP + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with DSIP's mechanism in protocol / scheduling / cycling protocols.
- DSIP + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with DSIP's mechanism in protocol / scheduling / cycling protocols.
Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants.
Lens-specific safety considerations for protocol / scheduling / cycling use of DSIP: Excellent safety record across decades of research use. No reported serious adverse events. Avoid combining with strong CNS depressants. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| DSIP | Neuropeptide (sleep) | ~7 min plasma; CNS effects longer | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Daily timing for DSIP?
Can I shift my schedule with travel?
Stack timing relative to training and meals?
Best practice for re-cycling?
What is the regulatory status of DSIP?
How should DSIP be stored and reconstituted?
Start a DSIP Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified DSIP and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 848 Da
- Sequence length
- 9 aa
- Half-life
- ~7 min plasma; CNS effects longer
- WADA
- Not on prohibited list
- FDA
- Unapproved
- Research
- Preclinical + small human series
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for DSIP unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for DSIP
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised